Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-01
2005-02-01
Rotman, Alan L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S385000, C514S456000, C548S331500, C546S268100, C549S406000
Reexamination Certificate
active
06849646
ABSTRACT:
The invention relates to compounds having formula (I), wherein R1, R2, R3, R4, R5, R7, R8, R11, Z, m and n have the meaning cited in claim 1, and to the physiologically acceptable salts and solvates which can be used as integrin inhibitors, especially in the prophylaxis and treatment of circulatory diseases, in case of thrombosis, myocardial infarction, coronary heart diseases, arteriosclerosis, osteoporosis, pathologic processes caused or propagated by angiogenesis and in tumor therapy.
REFERENCES:
patent: 5703075 (1997-12-01), Gammill
patent: 341 104 (1989-11-01), None
patent: 90 06921 (1990-06-01), None
patent: 91 19707 (1991-12-01), None
patent: 96 22288 (1996-07-01), None
Fittschen Claus
Goodman Simon
März Joachim
Raddatz Peter
Wiesner Matthias
Merck Patent GmbH
Millen White Zelano & Branigan P.C.
Robinson Binta
Rotman Alan L.
LandOfFree
Chromenone and chromanone derivatives as integrin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chromenone and chromanone derivatives as integrin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromenone and chromanone derivatives as integrin inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3461856